Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 17 of 1046 for:    scale | Norway

MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03874156
Recruitment Status : Recruiting
First Posted : March 14, 2019
Last Update Posted : March 15, 2019
Sponsor:
Collaborators:
The Hospital of Vestfold
Oslo University Hospital
University of Oslo
Information provided by (Responsible Party):
Vestre Viken Hospital Trust

Brief Summary:
The study aims to estimate the effect of atorvastatin on muscular symptom intensity in coronary patients with subjective statin-associated muscle symptoms (SAMS) and to determine the association with blood levels of atorvastatin and its metabolites, to obtain an objective marker for true SAMS. A randomized study will include 80 coronary patients with SAMS during ongoing atorvastatin therapy or previous muscle symptoms that led to discontinuation of atorvastatin. Patients will be randomized to 7-weeks treatment with atorvastatin 40 mg/day in the first period and matched placebo in the second 7-weeks period, or placebo in the first period and atorvastatin in the second period. A control group (n=40) without muscle symptoms will have 7 weeks open treatment with atorvastatin 40 mg/day. Blood samples will be collected at baseline and after each treatment period, and muscular symptom intensities will be rated by the patients weekly. The primary outcome is the difference in aggregated mean Visual Analogue Scale (VAS) scores between the last three weeks of atorvastatin treatment and of placebo treatment. The main purpose is to develop an objective marker for true SAMS, by comparing SAMS associated with blinded atorvastatin treatment with blood concentrations of atorvastatin and its metabolites. Diagnostic and discrimination performance will be determined. The study provides new clinical knowledge on SAMS in coronary patients and may contribute to more personalized statin treatment and monitoring, fewer side-effects and consequently improved adherence and lipid management in future practice.

Condition or disease Intervention/treatment Phase
Statin Adverse Reaction Drug: Atorvastatin 40mg Drug: Placebo Oral Tablet Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Prospective, randomized double-blinded placebo controlled cross-over phase 4 study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -a Randomized Controlled Trial
Actual Study Start Date : March 5, 2019
Estimated Primary Completion Date : December 21, 2019
Estimated Study Completion Date : December 21, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Intervention group
Atorvastatin 40 mg once daily
Drug: Atorvastatin 40mg
Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS

Placebo Comparator: Placebo group
Matched placebo tablet once daily
Drug: Placebo Oral Tablet
Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS




Primary Outcome Measures :
  1. Individual mean difference in muscular symptom intensity measured with a 0 (no symptoms) to 10 (worst imaginable symptoms) Visual Analogue Scale (VAS) score between treatment periods with statin and placebo [ Time Frame: 16 weeks following randomization ]
    Individual mean difference in muscular symptom (i.e. pain, aching, tenderness, stiffness, cramp and/or weakness) intensity between treatment periods with statin and placebo, reported by the patients over the last three weeks (i.e. week 4-7) measured with a 0 (no symptoms) to 10 (worst imaginable symptoms) Visual Analogue Scale (VAS) score with aggregated data from each subscale


Secondary Outcome Measures :
  1. The proportion of patients who report muscle symptoms on atorvastatin treatment and not on placebo (dichotomous Statin Associated Muscle Symptom classification) [ Time Frame: 16 weeks following randomization ]
  2. The correlation between individual muscular symptom intensity between treatment periods with statin and placebo over the last three weeks measured with 0 to 10 VAS score aggregated from each subscale, and levels of atorvastatin and metabolites [ Time Frame: 16 weeks following randomization ]
  3. Sensitivity, specificity, and area under the curve of blood concentrations of parent drug and the active metabolites of atorvastatin for the classification of true Statin Associated Muscle Symptoms (SAMS) [ Time Frame: 16 weeks following randomization ]
  4. Individual mean difference in likelihood of statin discontinuation between treatment periods with statin and placebo over the last three weeks (i.e. week 4-7) measured with 0 to 10 VAS score with aggregated data from each subscale. [ Time Frame: 16 weeks following randomization ]
  5. Statin adherence measured weekly with self-reported questionnaire methods during the study periods [ Time Frame: 16 weeks following randomization ]
    Statin adherence measured with self-reported questionnaires (numeric scale: <4/7, 5/7, 6/7 or 7/7) weekly during the treatment periods. Low statin adherence will be defined by taking statins less than 42 of 49 days during the 7 weeks treatment period

  6. Statin adherence measured with pill counts of returned packages [ Time Frame: 16 weeks following randomization ]
    Statin adherence measured with pill counts of returned packages. Low statin adherence will be defined by a total of >=8 returned pills during the treatment periods

  7. Statin adherence measured with direct liquid chromatography-tandem mass spectrometry methods [ Time Frame: 16 weeks following randomization ]
    Statin adherence measured with direct liquid chromatography-tandem mass spectrometry methods. Low statin adherence defined by dose-normalized statin and metabolites concentrations < 0.10 (nmol/L)/mg

  8. Levels of atorvastatin and its metabolites in blood plasma and white blood cells at study end [ Time Frame: 16 weeks following randomization ]
  9. Number of patients with new-onset coronary heart disease symptoms, intolerable muscle symptoms leading to discontinuation from the treatment arm, and elevated levels of creatine kinase (CK) and/or Alanine Aminotransferase (ALT) in blood [ Time Frame: 16 weeks following randomization ]
    Safety endpoints: i.New-onset coronary heart disease symptoms. ii Intolerable muscle symptoms leading to discontinuation from the treatment arm.iii elevated levels of creatine kinase (CK) and/or Alanine Aminotransferase (ALT) in blood



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years or older
  • First or recurrent diagnosis (myocardial infarction) or treatments (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Graft operation [CABG]) for a coronary heart disease (CHD) event at least 6 months prior to study start and prescribed atorvastatin (irrespective of dose)
  • Reporting muscle complaints (i.e. pain, weakness, tenderness, stiffness or cramp) that they attribute to atorvastatin therapy or atorvastatin discontinuation due to muscle complains
  • Signed informed consent and expected cooperation of the patient according to International Council for Harmonisation/Good Clinical Practice and national/local regulations

Exclusion Criteria:

  • First or recurrent diagnosis (myocardial infarction) or treatments (PCI or CABG) for a CHD event the a) past 12 months prior to study start in high risk patients (i.e. at least one of following comorbid conditions: systolic heart failure, >1 previous myocardial infarction, kidney failure, diabetes, and smokers) and b) the past 6 months prior to study start in low risk patients without any of the co-morbid conditions mentioned above and in patients who are not taking a statin at all

    . Patients with symptomatic peripheral artery disease and patients with familial hypercholesterolemia

  • Patient has any contraindications for atorvastatin listed in the Summary of Product Characteristics (i.e. known hypersensitivity to the ingredients, acute liver failure/ Alanine Aminotransferase > 3 times upper limit of the normal range in blood at study start, pregnancy and breastfeeding)
  • History of previous rhabdomyolysis, myopathy or liver failure due to statin treatment with Creatine Kinase > 10 times upper limit of the normal range or Alanine Aminotransferase > 3 times upper limit of the normal range.
  • Any condition (e.g. psychiatric illness, dementia) or situation, that in the investigator's opinion could put the subject at significant risk, confound the study results, interfere significantly with the subject participation in the study, or rendering informed consent unfeasible
  • Short life expectancy (<12 months) due to other medical conditions
  • Not being able to understand Norwegian.
  • Women of childbearing potential defined as all premenopausal female.
  • Participation in another randomized clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03874156


Contacts
Layout table for location contacts
Contact: john munkhaugen, MD, PhD + 47 97524194 johmun@vestreviken.no
Contact: Oscar Kristiansen, MD + 47 47682535 osckri@vestreviken.no

Locations
Layout table for location information
Norway
Vestre Viken Trust, Drammen Hospital Recruiting
Drammen, Buskerud, Norway, 3004
Contact: john munkhaugen    + 47 97524194    johmun@vestreviken.no   
Contact: Oscar Kristiansen    +47 47682535    osckri@vestreviken.no   
Hospital of Vestfold Trust Recruiting
Tønsberg, Vestfold, Norway, 3103
Contact: Jan Erik Otterstad, MD, PhD    +47 91662603    jan.erik.otterstad@siv.no   
Contact: john munkhaugen, MD, PhD    97524194    johmun@vestreviken.no   
Sponsors and Collaborators
Vestre Viken Hospital Trust
The Hospital of Vestfold
Oslo University Hospital
University of Oslo
Investigators
Layout table for investigator information
Principal Investigator: john munkhaugen, MD, PhD Vestre Viken Trust

Layout table for additonal information
Responsible Party: Vestre Viken Hospital Trust
ClinicalTrials.gov Identifier: NCT03874156     History of Changes
Other Study ID Numbers: REK 2018/2302
First Posted: March 14, 2019    Key Record Dates
Last Update Posted: March 15, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual participant data will be made available for other researchers
Time Frame: Data will be available within 5 years of study completion

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Atorvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors